| Abstract: | The purpose of this study was to investigate the relationship between cyclin D1expression and clinicopathological parameters in patients with prostate carcinoma. Weassessed cyclin D1 expression by conventional immunohistochemistry in 85 patients whounderwent radical prostatectomy for prostate carcinoma and 10 normal prostate tissuesamples retrieved from autopsies. We measured nuclear immunostaining in the entiretumor area and based the results on the percentage of positive tumor cells. Thepreoperative prostate-specific antigen (PSA) level was 8.68±5.16 ng/mL (mean±SD).Cyclin D1 staining was positive (cyclin D1 expression in >5% of tumor cells) in 64cases (75.4%) and negative (cyclin D1 expression in ≤5% of tumor cells) in 21 cases(including 15 cases with no immunostaining). Normal prostate tissues were negativefor cyclin D1. Among patients with a high-grade Gleason score (≥7), 86% of patientsdemonstrated cyclin D1 immunostaining of >5% (P<0.05). In the crude analysis ofcyclin D1 expression, the high-grade Gleason score group showed a mean expression of39.6%, compared to 26.9% in the low-grade Gleason score group (P<0.05). Perineuralinvasion tended to be associated with cyclin D1 expression (P=0.07), whereas cyclinD1 expression was not associated with PSA levels or other parameters. Our resultssuggest that high cyclin D1 expression could be a potential marker for tumoraggressiveness. |
